Perseus Trial News Today

Gabriel Hinojosa, PharmD, BCOP, explores unmet needs and social determinants in multiple myeloma care, envisioning treatment advancements amid evolving complexities and patient disparities.

Gabriel Hinojosa, PharmD, BCOP, looks beyond frontline regimens in multiple myeloma, and discusses treatment options, adverse events, and complexities in sequencing therapies.

The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.

A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.

The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.

Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.

Gabriel Hinojosa, PharmD, BCOP, provides insights on selecting the best treatment regimen, and considers comorbidities, adverse events, and therapy modifications in multiple myeloma treatment.

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

Gabriel Hinojosa, PharmD, BCOP, reviews head-to-head comparisons in multiple myeloma regimens and evaluates efficacy and safety implications in treatment selection.

Gabriel Hinojosa, PharmD, BCOP, analyzes eligibility factors and treatment shifts in multiple myeloma care, considering autologous stem cell transplant risks and evolving therapy approaches with daratumumab.